Galapagos NV ADR (NASDAQ:GLPG) — Market Cap & Net Worth
Market Cap & Net Worth: Galapagos NV ADR (GLPG)
Galapagos NV ADR (NASDAQ:GLPG) has a market capitalization of $1.89 Billion ($1.89 Billion) as of May 2, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #6478 globally and #1910 in its home market, demonstrating a -1.65% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Galapagos NV ADR's stock price $28.68 by its total outstanding shares 65897071 (65.90 Million). Analyse Galapagos NV ADR cash conversion from operations to see how efficiently the company converts income to cash.
Galapagos NV ADR Market Cap History: 2015 to 2026
Galapagos NV ADR's market capitalization history from 2015 to 2026. Data shows change from $4.14 Billion to $1.85 Billion (-5.27% CAGR).
Index Memberships
Galapagos NV ADR is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.08% | #154 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #693 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.67 Trillion | 0.11% | #99 of 263 |
Weight: Galapagos NV ADR's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Galapagos NV ADR Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Galapagos NV ADR's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.94x
Galapagos NV ADR's market cap is 1.94 times its annual revenue
Latest Price to Earnings (P/E) Ratio
6.71x
Galapagos NV ADR's market cap is 6.71 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $4.23 Billion | $129.52 Million | $54.01 Million | 32.66x | 78.31x |
| 2017 | $6.18 Billion | $127.09 Million | -$115.70 Million | 48.62x | N/A |
| 2018 | $6.05 Billion | $288.84 Million | -$29.26 Million | 20.93x | N/A |
| 2019 | $13.63 Billion | $834.90 Million | $149.84 Million | 16.32x | 90.96x |
| 2020 | $6.52 Billion | $478.05 Million | -$305.44 Million | 13.64x | N/A |
| 2021 | $3.63 Billion | $484.85 Million | -$125.42 Million | 7.49x | N/A |
| 2022 | $2.92 Billion | $241.25 Million | -$217.99 Million | 12.12x | N/A |
| 2023 | $2.68 Billion | $239.72 Million | $211.70 Million | 11.17x | 12.65x |
| 2024 | $1.81 Billion | $275.65 Million | $74.08 Million | 6.57x | 24.46x |
| 2025 | $2.15 Billion | $1.11 Billion | $320.90 Million | 1.94x | 6.71x |
Competitor Companies of GLPG by Market Capitalization
Companies near Galapagos NV ADR in the global market cap rankings as of May 2, 2026.
Key companies related to Galapagos NV ADR by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Galapagos NV ADR Historical Marketcap From 2015 to 2026
Between 2015 and today, Galapagos NV ADR's market cap moved from $4.14 Billion to $ 1.85 Billion, with a yearly change of -5.27%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.85 Billion | -14.37% |
| 2025 | $2.15 Billion | +18.91% |
| 2024 | $1.81 Billion | -32.35% |
| 2023 | $2.68 Billion | -8.40% |
| 2022 | $2.92 Billion | -19.50% |
| 2021 | $3.63 Billion | -44.30% |
| 2020 | $6.52 Billion | -52.14% |
| 2019 | $13.63 Billion | +125.45% |
| 2018 | $6.05 Billion | -2.15% |
| 2017 | $6.18 Billion | +46.07% |
| 2016 | $4.23 Billion | +2.08% |
| 2015 | $4.14 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of Galapagos NV ADR was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.89 Billion USD |
| MoneyControl | $1.89 Billion USD |
| MarketWatch | $1.89 Billion USD |
| marketcap.company | $1.89 Billion USD |
| Reuters | $1.89 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Galapagos NV ADR
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product c… Read more